Reata pharmaceuticals, inc. (RETA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Collaboration revenue

1,353

2,672

8,242

7,833

7,770

8,451

5,175

7,571

32,392

9,963

12,557

12,806

12,732

12,501

12,551

12,366

12,438

12,500

12,365

Expenses
Research and development

47,653

40,162

32,279

29,554

26,114

25,308

27,144

23,429

21,407

20,443

18,326

17,901

14,603

11,772

9,300

9,075

9,306

8,550

9,688

General and administrative

20,787

22,271

14,283

11,706

10,038

7,945

7,486

10,689

6,628

5,946

6,151

5,990

5,173

4,820

4,039

4,537

3,207

2,980

3,369

Depreciation

278

272

258

232

170

120

105

105

101

100

98

109

130

145

170

179

188

486

529

Total expenses

68,718

187,103

46,820

41,492

36,322

33,373

34,735

34,223

28,136

26,489

24,575

24,000

19,906

16,737

13,509

13,791

12,701

12,016

13,586

Investment income

-

-

1,311

1,705

-

-

1,094

357

335

-

198

73

81

101

62

28

23

9

8

Interest expense

-

-

2,389

2,413

-

-

2,360

903

509

-

484

468

5

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

-1,007

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

-

-

-

7

-

-

-

-

-

-

-3

-

-

-

-

-

-

-

-

Other income (expense), net

-3,814

-2,563

-1,078

-701

-600

-649

-1,266

-1,553

-174

-148

-289

-395

76

101

62

28

23

9

8

Loss before taxes on income

-71,179

-186,994

-39,656

-34,360

-29,152

-25,571

-30,826

-28,205

4,082

-16,674

-12,307

-11,589

-7,098

-4,135

-896

-1,397

-240

493

-1,213

(Benefit from) provision for taxes on income

-22,240

-52

38

20

2

-

9

6

-

-

1

2

-

1

1

-461

18

-140

482

Net loss

-48,939

-186,942

-39,694

-34,380

-29,154

-25,582

-30,835

-28,211

4,082

-16,674

-12,308

-11,591

-7,098

-4,136

-897

-936

-258

633

-1,695

Net loss per share—basic and diluted

-1.47

-6.10

-1.32

-1.14

-0.98

-

-1.07

-1.08

-

-

-0.50

-0.52

-

-0.20

-0.04

-0.05

-0.02

-

-

Weighted-average number of common shares used in net loss per share basic and diluted

33,222

31,647

30,110

30,069

29,830

-

28,704

26,178

-

-

24,845

22,365

-

22,389

22,324

18,562

15,990

-

-

Net (loss) income per share—basic

-

-

-

-

-

-

-

-

0.16

-

-

-

-0.32

-

-

-

-

0.04

-0.11

Net (loss) income per share—diluted

-

-

-

-

-

-

-

-

0.15

-

-

-

-0.32

-

-

-

-

0.04

-0.11

Weighted-average number of common shares used in net (loss) income per share basic

-

-

-

-

-

-

-

-

26,155

-

-

-

22,350

-

-

-

-

15,979

15,973

Weighted-average number of common shares used in net (loss) income per share diluted

-

-

-

-

-

-

-

-

26,633

-

-

-

22,350

-

-

-

-

16,149

15,973

License and milestone
Collaboration revenue

1,169

1,839

7,898

7,813

7,726

7,898

4,766

7,519

32,168

9,508

12,501

12,365

12,729

12,500

12,500

12,365

12,365

12,500

12,365

Other revenue
Collaboration revenue

184

833

344

20

44

553

409

52

224

455

56

441

3

1

51

1

73

-

-